WO2014193237A3 - Protéase de c. difficile - Google Patents

Protéase de c. difficile Download PDF

Info

Publication number
WO2014193237A3
WO2014193237A3 PCT/NL2014/050349 NL2014050349W WO2014193237A3 WO 2014193237 A3 WO2014193237 A3 WO 2014193237A3 NL 2014050349 W NL2014050349 W NL 2014050349W WO 2014193237 A3 WO2014193237 A3 WO 2014193237A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease
diff
peptide
invention further
clostridium difficile
Prior art date
Application number
PCT/NL2014/050349
Other languages
English (en)
Other versions
WO2014193237A2 (fr
Inventor
Hans Christiaan VAN LEEUWEN
Paul Jacob HENSBERGEN
Jan Wouter Drijfhout
Eduard KUIJPER
Jeroen CORVER
Original Assignee
Academisch Ziekenhuis Leiden H.O.D.N. Lumc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden H.O.D.N. Lumc filed Critical Academisch Ziekenhuis Leiden H.O.D.N. Lumc
Publication of WO2014193237A2 publication Critical patent/WO2014193237A2/fr
Publication of WO2014193237A3 publication Critical patent/WO2014193237A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un peptide contenant la séquence d'acides aminés A/P- A/P-V/P/I/C/T-P en tant que substrat pour la protéase CD2830 de Clostridium difficile. L'invention concerne, en outre, un nécessaire ou un dispositif comprenant ledit peptide, et ce, à des fins de détermination de la présence de Clostridium difficile dans un échantillon, ainsi que d'identification d'un agent capable de moduler l'activité de la protéase CD2830. L'invention concerne, en outre, une composition, de préférence une composition pharmaceutique, contenant un inhibiteur de l'activité de la protéase CD2830.
PCT/NL2014/050349 2013-05-30 2014-05-30 Protéase de c. difficile WO2014193237A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13169930 2013-05-30
EP13169930.8 2013-05-30
EP13197876 2013-12-17
EP13197876.9 2013-12-17

Publications (2)

Publication Number Publication Date
WO2014193237A2 WO2014193237A2 (fr) 2014-12-04
WO2014193237A3 true WO2014193237A3 (fr) 2015-03-19

Family

ID=50928203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2014/050349 WO2014193237A2 (fr) 2013-05-30 2014-05-30 Protéase de c. difficile

Country Status (1)

Country Link
WO (1) WO2014193237A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121544A1 (en) * 1997-09-15 2006-06-08 Annegret Boge Molecular modification assays
WO2009010765A2 (fr) * 2007-07-18 2009-01-22 Novacta Biosystems Limited Composes a base de lanthibiotique a activite antimicrobienne
US20100291100A1 (en) * 2009-03-27 2010-11-18 Gojo Industries, Inc. Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737977T2 (de) 1997-05-01 2008-04-17 Minnesota Mining And Manufacturing Company, St. Paul Fluorogene protease-substrate basierend auf farbstoffdimerisierung
CA2398583A1 (fr) 2000-02-11 2001-08-16 Cellomics, Inc. Biocapteurs peptidiques destines a la protease du charbon bacteridien

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121544A1 (en) * 1997-09-15 2006-06-08 Annegret Boge Molecular modification assays
WO2009010765A2 (fr) * 2007-07-18 2009-01-22 Novacta Biosystems Limited Composes a base de lanthibiotique a activite antimicrobienne
US20100291100A1 (en) * 2009-03-27 2010-11-18 Gojo Industries, Inc. Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACQUOT ET AL: "High affinity Grb2-SH3 domain ligand incorporating C<b>eta-substituted prolines in a Sos-derived decapeptide", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 3, 19 January 2007 (2007-01-19), pages 1439 - 1447, XP005823084, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2006.11.002 *
M. VIDAL ET AL: "Design of Peptoid Analogue Dimers and Measure of Their Affinity for Grb2 SH3 Domains +", BIOCHEMISTRY, vol. 43, no. 23, 1 June 2004 (2004-06-01), pages 7336 - 7344, XP055087222, ISSN: 0006-2960, DOI: 10.1021/bi030252n *

Also Published As

Publication number Publication date
WO2014193237A2 (fr) 2014-12-04

Similar Documents

Publication Publication Date Title
CA3081446A1 (fr) Methodes et compositions pour analyse de polypeptides
MX2021012926A (es) Moduladores de la proteolisis basados en imida y metodos de uso asociados.
MX2021010482A (es) Compuestos y metodos para la degradacion mejorada de proteinas especificas.
MX2017015605A (es) Moduladores de proteolisis basados en imida y metodos de uso asociados.
MX2022009478A (es) Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
MX2020003260A (es) Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
SG10201806926YA (en) Method for masking bitterness of composition containing collagen peptide
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
MX2016015511A (es) Compuestos que comprenden grupo auto-destructivo.
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
BR112013029525A8 (pt) Proteínas de fusão terapêuticas
MX2017005575A (es) Formulacion farmaceutica de anticuerpos anti-tnf alfa.
WO2013020108A3 (fr) Inhibiteurs du recyclage de l&#39;acide biliaire dans le traitement du pancréas
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
NZ727701A (en) Platinum compounds, compositions, and uses thereof
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
PH12016500101A1 (en) Protease-resistant peptide ligands
GB201014028D0 (en) In-situ reagent
PE20160218A1 (es) Metodos para controlar los niveles de fucosilacion en proteinas
WO2014172638A3 (fr) Inhibiteurs de protéases de désubiquitination
EA201792608A3 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
MX2017007554A (es) Detergentes y agentes de limpieza que comprende una combinacion de amilasa y proteasa.
EP3696190A3 (fr) Procédés
EP3337791A4 (fr) Inhibiteurs d&#39;enzymes peptidyl arginine désiminases (pad) et leurs utilisations
WO2012166848A3 (fr) Méthodes et compositions pour la détection de toxines de clostridium difficile fonctionnelles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14729469

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14729469

Country of ref document: EP

Kind code of ref document: A2